Voth Lynden S, O'Connor Joseph J, Kerr Catherine M, Doerger Ethan, Schwarting Nancy, Sperstad Parker, Johnson David K, Fehr Anthony R
bioRxiv. 2021 Mar 31:2021.03.30.437796. doi: 10.1101/2021.03.30.437796.
All coronaviruses (CoVs) contain a macrodomain, also termed Mac1, in non-structural protein 3 (nsp3) which binds and hydrolyzes ADP-ribose covalently attached to proteins. Despite several reports demonstrating that Mac1 is a prominent virulence factor, there is still a limited understanding of its cellular roles during infection. Currently, most of the information regarding the role of CoV Mac1 during infection is based on a single point mutant of a highly conserved asparagine-to-alanine mutation, which is known to largely eliminate Mac1 ADP-ribosylhydrolase activity. To determine if Mac1 ADP-ribose binding separately contributes to CoV replication, we compared the replication of a murine hepatitis virus (MHV) Mac1 mutant predicted to dramatically reduce ADP-ribose binding, D1329A, to the previously mentioned asparagine mutant, N1347A. D1329A and N1347A both replicated poorly in bone-marrow derived macrophages (BMDMs), were inhibited by PARP enzymes, and were highly attenuated . However, D1329A was significantly more attenuated than N1347A in all cell lines tested that were susceptible to MHV infection. In addition, D1329A retained some ability to block IFN-β transcript accumulation compared to N1347A, indicating that these two mutants impacted distinct Mac1 functions. Mac1 mutants predicted to eliminate both binding and hydrolysis activities were unrecoverable, suggesting that the combined activities of Mac1 may be essential for MHV replication. We conclude that Mac1 has multiple roles in promoting the replication of MHV, and that these results provide further evidence that Mac1 could be a prominent target for anti-CoV therapeutics.
In the wake of the COVID-19 epidemic, there has been a surge to better understand how CoVs replicate, and to identify potential therapeutic targets that could mitigate disease caused by SARS-CoV-2 and other prominent CoVs. The highly conserved macrodomain, also termed Mac1, is a small domain within non-structural protein 3. It has received significant attention as a potential drug target as previous studies demonstrated that it is essential for CoV pathogenesis in multiple animal models of infection. However, the various roles and functions of Mac1 during infection remain largely unknown. Here, utilizing recombinant Mac1 mutant viruses, we have determined that different biochemical functions of Mac1 have distinct roles in the replication of MHV, a model CoV. These results indicate that Mac1 is more important for CoV replication than previously appreciated, and could help guide the development of inhibitory compounds that target unique regions of this protein domain.
所有冠状病毒(CoV)在非结构蛋白3(nsp3)中都含有一个大结构域,也称为Mac1,它能结合并水解共价连接到蛋白质上的ADP-核糖。尽管有几份报告表明Mac1是一个重要的毒力因子,但对其在感染过程中的细胞作用仍了解有限。目前,关于CoV Mac1在感染过程中作用的大多数信息是基于一个高度保守的天冬酰胺到丙氨酸突变的单点突变体,已知该突变体在很大程度上消除了Mac1的ADP-核糖水解酶活性。为了确定Mac1的ADP-核糖结合是否单独有助于CoV复制,我们比较了预测会显著降低ADP-核糖结合的鼠肝炎病毒(MHV)Mac1突变体D1329A与上述天冬酰胺突变体N1347A的复制情况。D1329A和N1347A在骨髓来源的巨噬细胞(BMDM)中复制都很差,受到PARP酶的抑制,并且高度减毒。然而,在所有测试的对MHV感染敏感的细胞系中,D1329A比N1347A的减毒程度明显更大。此外,与N1347A相比,D1329A仍保留一些阻断IFN-β转录本积累的能力,表明这两个突变体影响了Mac1的不同功能。预测消除结合和水解活性的Mac1突变体无法恢复,这表明Mac1的联合活性可能对MHV复制至关重要。我们得出结论,Mac1在促进MHV复制中具有多种作用,并且这些结果进一步证明Mac1可能是抗CoV治疗的一个重要靶点。
在COVID-19疫情之后,人们迫切希望更好地了解CoV如何复制,并确定可以减轻由SARS-CoV-2和其他重要CoV引起的疾病的潜在治疗靶点。高度保守的大结构域,也称为Mac1,是非结构蛋白3中的一个小结构域。由于先前的研究表明它在多种感染动物模型中对CoV发病机制至关重要,因此它作为潜在的药物靶点受到了广泛关注。然而,Mac1在感染过程中的各种作用和功能仍 largely未知。在这里,利用重组Mac1突变病毒,我们确定了Mac1的不同生化功能在模型CoV——MHV的复制中具有不同的作用。这些结果表明,Mac1对CoV复制比以前认为的更重要,并且可以帮助指导针对该蛋白结构域独特区域的抑制性化合物的开发。